 |
 |
 |
 |
|
|
Conference Director:
William W. Li, M.D.
President, The Angiogenesis Foundation
| 7:00 | Registration and Buffet Breakfast |
| 7:45 | Welcome Remarks William W. Li, M.D. President and Medical Director, The Angiogenesis Foundation |
| 8:00 | New Directions in the Clinical Application
of Antiangiogenic Therapy Judah Folkman, M.D. Andrus Professor of Pediatric Surgery and Professor of Cell Biology, Harvard Medical School Director, Vascular Biology Program, Children’s Hospital Boston |
| 8:45 | Genes Distinguishing Physiological
from Pathological Angiogenesis Brad St. Croix, Ph.D. Head of Tumor Angiogenesis Section, National Cancer Institute |
| 9:15 | Tumor Suppression by p53-mediated Angiogenesis
Inhibition Jose Teodoro, Ph.D. Assistant Professor McGill Cancer Centre and Department of Biochemistry, McGill University, Canada |
| 9:45 | Networking Refreshment Break |
| 10:15 | Dll4 Signaling Through Notch1 Regulates
Formation of Tip Cells During Angiogenesis Mats Hellstrom, Ph.D. CEO and Co-Founder, AngioGenetics, Sweden |
| 10:45 | CD105 as a Target as an Antiangiogenic
Therapy Charles P. Theuer, M.D., Ph.D. CEO and President, TRACON Pharmaceuticals |
| 11:15 | Role of VEGF-(xxx)B, an Inhibitory Form
of VEGF, in Tumor Growth David O. Bates, Ph.D. Director, Microvascular Research Laboratories, University of Bristol, United Kingdom |
| 11:45 | A Systems Biology Exploration of Angiogenesis
Regulation and Phenotypic Drug Discovery Jian Young Shou, Ph.D. Senior Research Scientist, Oncology Division, Lilly Research Laboratories |
| 12:15 | Networking Luncheon |
| Special Regulatory Lecture | |
| 1:45 | Modern Issues in Regulating Drug Development:
Perspectives from the World of Antiangiogenesis Paul T. Kim, MPP, JD Partner, Foley & Hoag LLP Former Deputy Director for Health Policy (Sen. Kennedy), U.S. Senate Former Policy Analyst, Office of the Commissioner, U.S. FDA |
| 2:15 | Cancer and Angiogenesis: The Lipid Link Genevieve Hansen, Ph.D. Vice President, Research, LPath, Inc. |
| 2:45 | PCK3145 - A Novel Multi-Targeted Signaling
Peptide Derived from a Naturally Occurring Protein, for the Treatment of
Castrate Metastatic Prostate Cancer (CMPC) Chandra Panchal, Ph.D. Executive Vice President, Business Development, Licensing & Intellectual Property, Ambrilia Biopharma, Canada |
| 3:15 | Networking Refreshment Break |
| 3:45 | Targeting Tumor Angiogenesis by Blocking
Dll4-mediated Notch Signaling Minhong Yan, Ph.D. Scientist, Genentech, Inc. |
| 4:15 | Controlling Angiogenesis in Tumors
- VEGF and Other Pathways |
| 4:45 | Identification and Characterization
of Metastasis Progression Genes Don Nguyen, Ph.D. Senior Fellow, Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center |
| 5:15 | MODERATED DISCUSSION |
| 5:45 | Networking Cocktail Reception |
| 7:00 | Registration and Buffet Breakfast |
| 7:40 | Chairperson’s Remarks and Recap of Day One |
| Special Workshop | |
| 7:45 | Hypertension Management in Antiangiogenic
Therapy Randall Zusman, M.D. Director, Division of Hypertension, Massachusetts General Hospital |
| 8:15 | Anti-VEGF Therapy for Brain Tumors:
Evidence for Safety and Efficacy Tracey T. Batchelor, M.D. Chief, Division of Neuro-Oncology, Massachusetts General Hospital |
| 8:45 | VEGF Trap (Aflibercept): Update on Clinical
Development William P. Tew, M.D. Assistant Attending Physician, Memorial Sloan-Kettering Cancer Center |
| 9:15 | Angiocept (CT-322), a Novel Antiangiogenesis
Agent, Based on Adnectins Eric Furfine, Ph.D. Senior Vice President, Research and Preclinical Development, Adnexus Therapeutics |
| 9:45 | VEGF Inhibition and Beyond: Multi-targeting
with Sunitinib to Improve Tumor Response and Clinical Outcome in Kidney
Cancer M. Dror Michaelson, M.D., Ph.D. Assistant Professor of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital |
| 10:15 | Networking Refreshment Break |
| 10:45 | Multikinase Targeting of Hepatocellular
Carcinoma Andrew Zhu, M.D., Ph.D. Assistant Professor, Department of Medicine, Harvard Medical School Assistant Physician, Hematology/Oncology, Massachusetts General Hospital |
| 11:15 | Clinical Experience with mTOR Inhibitors:
an Emerging Strategy for Antiangiogenesis Therapy David McDermott, M.D. Clinical Director, Biologic Therapy Program, Beth Israel Deaconess Medical Center, Harvard Medical School |
| 11:45 | The BRiTE Study: Long-term Experience
and Outcomes with Antiangiogenic Therapy in Colorectal Cancer Axel Grothey, M.D. Senior Associate Consultant Division of Medical Oncology, Mayo Clinic Vice Chair, GI Committee, North Central Cancer Treatment Group |
| 12:15 | Antiangiogenic Therapy Side Effects:
Manifestations, Mechanisms, and Management Rebecca Suk Heist, M.D., MPH Assistant in Medicine, Massachusetts General Hospital Instructor in Medicine, Harvard Medical School |
| 12:45 | Networking Luncheon |
| 2:00 | Angiogenesis Imaging in Clinical
Drug Development: For Decision Making or Decorations? |
| Special Workshop | |
| 2:30 | Overcoming Skin Complications in
Targeted Therapy |
| 3:15 | Refreshment Break |
|
|
| 3:30 | Cell Suicide: Programmed Cell Death
in Development and Disease H. Robert Horvitz, Ph.D. 2002 Nobel Laureate in Medicine or Physiology David H. Koch Professor of Biology, Massachusetts Institute of Technology Investigator, Howard Hughes Medical Institute |
| 4:30 | Investing in Private and
Public Antiangiogensis Therapy Companies – Why Is It a Hot Area and
Why Will It Stay that Way? Frank Gentile, Ph.D. Senior Vice President of Research, Hambrecht & Quist Capital Management |
| 5:00 | Drug Pricing, Reimbursement and Competition:
Resolving the Tensions in Modern Oncology Drug Richard Frank, Ph.D. Professor of Health Economics in the Department of Health Care Policy, Harvard Medical School |
| 5:30 | MODERATED DISCUSSION |
| 5:45 | Closing Remarks |
| 6:00 | Close of Conference |
Program Sponsors: This conference is being sponsored, in part, by educational grants from: Genentech BioOncology, GlaxoSmithKline Oncology, CoMentis, Eli Lilly, AstraZeneca, OXiGENE, Sanofi-Aventis, Ambrilia BioPharma, Biogen Idec, and other generous donors and supporters of the Angiogenesis Foundation, a 501(c)(3) nonprofit organization.
Via Fax:
Please send completed form to 617-576-5808 (attention: Conference Registration)
Call for Details:
Please call 617-576-5708 and ask for Colleen
Carney, Conference Manager.